CAS 1357920-84-3
:Belizatinib
Description:
Belizatinib is a small molecule inhibitor primarily designed to target specific tyrosine kinases, particularly those involved in cancer cell proliferation and survival. It is classified as a kinase inhibitor and has shown potential in the treatment of various malignancies, particularly those associated with genetic mutations that lead to aberrant signaling pathways. The compound's mechanism of action typically involves the selective inhibition of the target kinases, which can disrupt the signaling cascades that promote tumor growth. Belizatinib is characterized by its ability to penetrate cellular membranes, allowing it to exert its effects intracellularly. Additionally, it may exhibit pharmacokinetic properties that influence its absorption, distribution, metabolism, and excretion (ADME) profile, which are crucial for its therapeutic efficacy and safety. As with many investigational drugs, ongoing research and clinical trials are essential to fully elucidate its therapeutic potential, optimal dosing regimens, and any associated side effects.
Formula:C33H44FN5O3
Synonyms:- Benzamide, 4-fluoro-N-[6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-1-[cis-4-[[(1-methylethyl)amino]carbonyl]cyclohexyl]-1H-benzimidazol-2-yl]-
- CS-2493
- TSR-011
- Belizatinib (TSR011)
- Belizatinib
- TSR011; TSR011; TSR 011; BELIZATINIB
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Formula:C33H44FN5O3Purity:99.33% - 99.44%Color and Shape:SolidMolecular weight:577.73TSR-011
CAS:<p>Inhibitor of ALK and TRK kinases</p>Formula:C33H44FN5O3Purity:Min. 95%Molecular weight:577.73 g/mol
